Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
* Primary : To determine the safety profile of each treatment group.
* Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
Non-Small-Cell Lung Carcinoma
DRUG: docetaxel and cisplatin|RADIATION: radiotherapy
overall response rate, in population of patients eligible and evaluable for response|time to progression, from the date of start treatment until progression|duration of response, only on responders
* Primary : To determine the safety profile of each treatment group.
* Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.